No Data
No Data
Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
Express News | China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder
Express News | Marinus Pharmaceuticals- in Marigold Trial, Ganaxolone Was Generally Well-Tolerated & Showed Safety Profile Consistent With Previous Clinical Trials
Express News | Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated With Cdkl5 Deficiency Disorder
Ladenburg Thalmann Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating, Maintains Target Price $4
Truist Financial Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
No Data